The druggable genome: Evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Annual Review of Pharmacology and Toxicology

• Publication date

  2014-01-06

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1146/annurev-pharmtox-011613-135943PMID 24016212
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A transposase strategy for creating libraries of circularly permuted proteins

  2012cited by this paper
• Toll-like receptor blocker slows beta cell death in type 1 diabetes

  2012cited by this paper
• Recent advances in the pathophysiology and pharmacological treatment of obesity

  2012cited by this paper
• Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons

  2012cited by this paper
• Outlook for the next 5 years in drug innovation

  2012cited by this paper
• Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study

  2012cited by this paper
• Reorganizing the protein space at the Universal Protein Resource (UniProt)

  2011cited by this paper
• Trends in the exploitation of novel drug targets

  2011cited by this paper
• Evidence for Irreversible Inhibition of Glycogen Synthase Kinase-3β by Tideglusib*

  2011cited by this paper
• DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs

  2010cited by this paper
• Fumagillin Reduces Adipose Tissue Formation in Murine Models of Nutritionally Induced Obesity

  2010cited by this paper
• How to improve R&D productivity: the pharmaceutical industry's grand challenge

  2010cited by this paper
• Alzheimer's disease: strategies for disease modification

  2010cited by this paper
• Mapping the human membrane proteome: a majority of the human membrane proteins can be classified according to function and evolutionary origin

  2009cited by this paper
• Targeting cancer with small molecule kinase inhibitors

  2009cited by this paper
• Anti‐CD3 mAbs for treatment of type 1 diabetes

  2009cited by this paper
• Structural diversity of G protein-coupled receptors and significance for drug discovery

  2008cited by this paper
• Lorcaserin, a Novel Selective Human 5-Hydroxytryptamine2C Agonist: in Vitro and in Vivo Pharmacological Characterization

  2008cited by this paper
• Interleukin-1-receptor antagonist in type 2 diabetes mellitus.

  2007cited by this paper
• Assessment of the anti-obesity effects of the TNP-470 analog, CKD-732.

  2007cited by this paper
• Drugs, their targets and the nature and number of drug targets

  2007cited by this paper
• Drugs, their targets and the nature and number of drug targets

  2006cited by this paper
• How many drug targets are there?

  2006cited by this paper
• TCDB: the Transporter Classification Database for membrane transport protein analyses and information

  2005cited by this paper
• Keynote review: Is declining innovation in the pharmaceutical industry a myth?

  2005cited by this paper
• DrugBank: a comprehensive resource for in silico drug discovery and exploration

  2005cited by this paper
• The druggable genome

  2002cited by this paper
• Protein kinases — the major drug targets of the twenty-first century?

  2002cited by this paper
• Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.

  2001cited by this paper
• A Functional-Phylogenetic Classification System for Transmembrane Solute Transporters

  2000cited by this paper
• The protein tyrosine kinase family of the human genome

  2000cited by this paper
• Sources of Cancer Research Funding in the United States

  1999cited by this paper
• Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

  1997cited by this paper
• Genomic sciences and the medicine of tomorrow

  1996cited by this paper
• Enzyme nomenclature 1992. Recommendations of the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology on the Nomenclature and Classification of Enzymes.

  1992cited by this paper
• Goodman & Gilman's The Pharmacological Basis of Therapeutics

  1985cited by this paper
• Molecular Neuroscience Review Article Modulation of Gsk-3 as a Therapeutic Strategy on Tau Pathologies Role and Regulation of Gsk-3 Activity

  year unknowncited by this paper

• Protein structural dynamics in covalent drug design: insights from irreversible and reversible covalent inhibitors.

  2026cites this paper
• Results of a large scale study of the binding of 50 type II inhibitors to 348 kinases: The role of protein reorganization

  2026cites this paper
• Activation of GPR97/ADGRG3 by its tethered agonist, but not by beclomethasone, induces neutrophil polarization and migration.

  2026cites this paper
• Strategic advances for cryo-EM structural studies of small (<100 kDa) GPCRs

  2026cites this paper
• Membrane Proteins: Targets That Should Not Be Overlooked for Assessing Human and Ecological Health Effects of Chemicals.

  2025cites this paper
• Genomics of drug target prioritization for complex diseases

  2025cites this paper
• A Review of Wound Healing Potential of Soodan (Camphor) and Its Integration in Siddha Medicine

  2025cites this paper
• G Protein-Coupled Receptor Heteromers in Brain: Functional and Therapeutic Importance in Neuropsychiatric Disorders.

  2025cites this paper
• The Orphan Receptor GPR151: Discovery, Expression, and Emerging Biological Significance

  2025cites this paper
• GPR97/ADGRG3 is activated by its tethered peptide agonist and not by steroids to induce neutrophil polarization and migration

  2025cites this paper
• Prioritising research on endocrine disruption in the marine environment: a global perspective

  2025cites this paper
• Monocarbonyl synthetic curcumin analogues with antitumour potential. Chemical and biological aspects

  2025cites this paper
• Prioritization of Potential Drugs Through Pathway-Based Drug Repurposing and Network Proximity Analysis

  2025cites this paper
• GPCR Sense Communication Among Interaction Nematodes with Other Organisms

  2025cites this paper
• At The Interface: Small-Molecule Inhibitors of Soluble Cytokines.

  2025cites this paper
• Overcoming research bias: The untapped potential of biomedically important but understudied proteins

  2025cites this paper
• Recent developments of topoisomerase inhibitors: Clinical trials, emerging indications, novel molecules and global sales.

  2024cites this paper
• Histone deacetylases and their inhibitors in inflammatory diseases.

  2024cites this paper
• Small-molecule probe for IBD risk variant GPR65 I231L alters cytokine signaling networks through positive allosteric modulation

  2024cites this paper
• Molecular Bidents with Two Electrophilic Warheads as a New Pharmacological Modality

  2024cites this paper
• GPR97 deficiency suppresses Wnt/β‐catenin signaling in hypertensive nephropathy

  2024cites this paper
• Advances in structure-based drug design: The potential for precision therapeutics in psychiatric disorders.

  2024cites this paper
• The Role of Liquid-Liquid Phase Separation in the Accumulation of Pathological Proteins: New Perspectives on the Mechanism of Neurodegenerative Diseases

  2024cites this paper
• Assessing Protein-Protein Docking Protocols: Case Studies of G-Protein-Coupled Receptor Interactions.

  2024cites this paper
• Discoveries of GPR39 as an evolutionarily conserved receptor for bile acids and of its involvement in biliary acute pancreatitis

  2024cites this paper
• Redefining the Game: MVAE-DFDPnet’s Low-Dimensional Embeddings for Superior Drug-Protein Interaction Predictions

  2024cites this paper
• Exploring Scoring Function Space: Developing Computational Models for Drug Discovery.

  2023cites this paper
• Orphan G Protein-Coupled Receptor GPR37 as an Emerging Therapeutic Target.

  2023cites this paper
• Stable Binding of Full‐Length Chemerin Is Driven by Negative Charges in the CMKLR1 N Terminus

  2023cites this paper
• ACE2 Activation by Tripeptide IRW (Ile-Arg-Trp) Depends on the G Protein-Coupled Receptor 30 Signaling Cascade.

  2023cites this paper
• Rethinking c-Fos for understanding drug action in the brain.

  2023cites this paper
• Mechanistic considerations for adenosine-lidocaine-magnesium (ALM) in controlling coagulopathy.

  2023cites this paper
• Simultaneous activation of CXC chemokine receptor 4 and histamine receptor H1 enhances calcium signaling and cancer cell migration

  2023cites this paper
• Study of G protein coupling receptors

  2023cites this paper
• Second All-Russian school of medical chemistry for young scientists

  2023cites this paper
• Co-dependent regulation of p-BRAF and potassium channel KCNMA1 levels drives glioma progression

  2023cites this paper
• Long way up: rethink diseases in light of phase separation and phase transition

  2023cites this paper
• Beyond the Nucleus: Plastic Chemicals Activate G Protein-Coupled Receptors

  2023cites this paper
• Status of β1-Adrenoceptor Signal Transduction System in Cardiac Hypertrophy and Heart Failure

  2023cites this paper
• PhosphoDisco: A Toolkit for Co-regulated Phosphorylation Module Discovery in Phosphoproteomic Data

  2023cites this paper
• Smart nanoparticles for cancer therapy

  2023cites this paper
• GPR114/ADGRG5 is activated by its tethered peptide agonist because it is a cleaved adhesion GPCR

  2023cites this paper
• Dual N6/C7-Substituted 7-Deazapurine and Tricyclic Ribonucleosides with Affinity for G Protein-Coupled Receptors.

  2023cites this paper
• Construction and Applications of Mammalian Cell-Based DNA-Encoded Peptide/Protein Libraries.

  2023cites this paper
• Strategic Approaches to Improvise Peptide Drugs as Next Generation Therapeutics

  2023cites this paper
• Functional genomic analysis of Candida albicans protein kinases reveals modulators of morphogenesis in diverse environments

  2023cites this paper
• Recent developments of phosphodiesterase inhibitors: Clinical trials, emerging indications and novel molecules

  2022cites this paper
• The druggable schizophrenia genome: from repurposing opportunities to unexplored drug targets

  2022cites this paper
• Intersection of the Orphan G Protein-Coupled Receptor, GPR19, with the Aging Process

  2022cites this paper
• Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New Drugs in Clinical Trials and Global Sales

  2022cites this paper
• Comprehensive analysis reveals potential hub genes and therapeutic drugs in an acquired lymphedema model

  2022cites this paper
• The Pursuit of Enzyme Activation: A Snapshot of the Gold Rush.

  2022cites this paper
• NPFFR2 Contributes to the Malignancy of Hepatocellular Carcinoma Development by Activating RhoA/YAP Signaling

  2022cites this paper
• The Many Faces of G Protein-Coupled Receptor 143, an Atypical Intracellular Receptor

  2022cites this paper
• The druggable schizophrenia genome: from repurposing opportunities to unexplored drug targets

  2022cites this paper
• OMICs Technologies for Natural Compounds-based Drug Development.

  2022cites this paper
• Increased anxiety-like behaviors in Adgra1-/- male but not female mice are attributable to elevated neuron dendritic density, upregulated PSD95 expression, and abnormal activation of the PI3K/AKT/GSK-3β and MEK/ERK pathways.

  2022cites this paper
• Trends in Drug Delivery Systems for Natural Bioactive Molecules to Treat Health Disorders: The Importance of Nano-Liposomes

  2022cites this paper
• NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancer

  2022cites this paper
• Dissection of the polygenic architecture of neuronal Aβ production using a large sample of individual iPSC lines derived from Alzheimer’s disease patients

  2022cites this paper
• High‐throughput metabolomics predicts drug–target relationships for eukaryotic proteins

  2022cites this paper
• The Chemerin Receptor CMKLR1 Requires Full‐Length Chemerin for High Affinity in Contrast to GPR1 as Demonstrated by a New Nanoluciferase‐Based Binding Assay

  2022cites this paper
• Structure and Cooperativity in Substrate-Enzyme Interactions: Perspectives on Enzyme Engineering and Inhibitor Design.

  2022cites this paper
• Visualizing G protein-coupled receptor homomers using photoactivatable dye localization microscopy.

  2022cites this paper
• Systematic illumination of druggable genes in cancer genomes

  2022cites this paper
• Synthesis, In Vitro and In Silico Anticancer Activity of New 4-Methylbenzamide Derivatives Containing 2,6-Substituted Purines as Potential Protein Kinases Inhibitors

  2021cites this paper
• GPCRs Are Optimal Regulators of Complex Biological Systems and Orchestrate the Interface between Health and Disease

  2021cites this paper
• Novel Fluorinated Spermine and Small Molecule PEI to Deliver Anti-PD-L1 and Anti-VEGF siRNA for Highly Efficient Tumor Therapy

  2021cites this paper
• NMR spectroscopy of lipidic cubic phases

  2021cites this paper
• Evidence of G-Protein-Coupled Receptors (GPCR) in the Parasitic Protozoa Plasmodium falciparum—Sensing the Host Environment and Coupling within Its Molecular Signaling Toolkit

  2021cites this paper
• Corticotropin releasing hormone receptor 2 antagonist, RQ-00490721, for the prevention of pressure overload-induced cardiac dysfunction.

  2021cites this paper
• An update on extra-oral bitter taste receptors

  2021cites this paper
• Trends in kinase drug discovery: targets, indications and inhibitor design

  2021cites this paper
• Transcriptome Profiling of Dysregulated GPCRs Reveals Overlapping Patterns across Psychiatric Disorders and Age-Disease Interactions

  2021cites this paper
• Drugging the Undruggable: How Isoquinolines and PKA Initiated the Era of Designed Protein Kinase Inhibitor Therapeutics.

  2021cites this paper
• Motions around conserved helical weak spots facilitate GPCR activation

  2021cites this paper
• Resistance mechanisms of Cryptococcus spp. and plant compounds as tools to combat them

  2021cites this paper
• Systems Pharmacology: Enabling Multidimensional Therapeutics

  2021cites this paper
• Recent developments of HDAC inhibitors: Emerging indications and novel molecules

  2021cites this paper
• A Diversity‐Oriented Approach to Large Libraries of Artificial Macrocycles

  2021cites this paper
• Transient Transfection and Expression of Eukaryotic Membrane Proteins in Expi293F Cells and Their Screening on a Small Scale: Application for Structural Studies.

  2021cites this paper
• Targeting β-Arrestins in the Treatment of Psychiatric and Neurological Disorders

  2021cites this paper
• Comparative phosphoproteomic analysis unravels MAPK1 regulated phosphoproteins in Leishmania donovani.

  2021cites this paper
• Vasopressin V2 is a promiscuous G protein-coupled receptor that is biased by its peptide ligands

  2021cites this paper
• The evolution of commercial drug delivery technologies

  2021cites this paper
• Strategies towards Targeting Gαi/s Proteins: Scanning of Protein‐Protein Interaction Sites To Overcome Inaccessibility

  2021cites this paper
• A structural perspective on the design of decoy immune modulators.

  2021cites this paper
• Structural basis for the binding of a selective inverse agonist AF64394 with the human G-protein coupled receptor 3 (GPR3)

  2021cites this paper
• Computational structure modeling for diverse categories of macromolecular interactions.

  2020cites this paper
• Therapeutic efficacy of liposomal Grb2 antisense oligodeoxynucleotide (L-Grb2) in preclinical models of ovarian and uterine cancer

  2020cites this paper
• Future avenues for Alzheimer's disease detection and therapy: Liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery.

  2020cites this paper
• Homogeneous Dual-Parametric-Coupled Assay for Simultaneous Nucleotide Exchange and KRAS/RAF-RBD Interaction Monitoring

  2020cites this paper
• Exploration of Target Spaces in the Human Genome for Protein and Peptide Drugs

  2020influential citation
• Soluble ligands as drug targets

  2020cites this paper
• Dynamic protein interfaces and conformational landscapes of membrane protein complexes.

  2020cites this paper
• Targeting G protein-coupled receptors in cancer therapy.

  2020cites this paper
• Mechanisms of adhesion G protein–coupled receptor activation

  2020cites this paper
• Discovery of Plasmodium falciparum SR12 as a GOLD-Domain seven transmembrane protein regulating GPCR trafficking in mammalian cells

  2020cites this paper
• G-Protein-Coupled Receptors in CNS: A Potential Therapeutic Target for Intervention in Neurodegenerative Disorders and Associated Cognitive Deficits

  2020cites this paper
• The Application of Negative Design to Design More Desirable Virtual Screening Library.

  2020cites this paper